GSK (LON:GSK) Receives Hold Rating from Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank reiterated a Hold rating on GSK with a GBX 1,900 price target, implying only about a 1.0% upside from the stock's current level.
• Analyst consensus remains a Hold (MarketBeat average target GBX 2,034.29), with 2 Buys, 4 Holds and 1 Sell among covering analysts.
• GSK shares rose about 1.3% to GBX 1,881 on the day; the company has a market capitalization of £75.18 billion and a P/E of 13.24, providing valuation context for investors.

GSK (LON:GSK - Get Free Report)'s stock had its "hold" rating reiterated by equities researchers at Deutsche Bank Aktiengesellschaft in a research report issued on Wednesday,Digital Look reports. They presently have a GBX 1,900 price objective on the stock. Deutsche Bank Aktiengesellschaft's price target would suggest a potential upside of 1.01% from the company's current price.

A number of other research analysts have also issued reports on GSK. UBS Group reiterated a "neutral" rating and issued a GBX 1,940 target price on shares of GSK in a research note on Friday, January 23rd. Citigroup lowered their target price on shares of GSK from GBX 2,250 to GBX 2,100 and set a "neutral" rating on the stock in a research note on Wednesday. Jefferies Financial Group reiterated a "buy" rating and issued a GBX 2,500 target price on shares of GSK in a research note on Tuesday, April 14th. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of GSK in a research note on Wednesday, January 7th. Finally, Shore Capital Group reiterated a "buy" rating on shares of GSK in a research note on Wednesday, March 25th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, GSK has an average rating of "Hold" and an average target price of GBX 2,034.29.

GSK Stock Up 1.3%

LON GSK traded up GBX 24 during trading on Wednesday, hitting GBX 1,881. 165,761,813 shares of the company traded hands, compared to its average volume of 11,059,457. GSK has a 12 month low of GBX 1,288.61 and a 12 month high of GBX 2,282. The business has a fifty day simple moving average of GBX 2,077.02 and a 200 day simple moving average of GBX 1,929.05. The company has a current ratio of 0.79, a quick ratio of 0.73 and a debt-to-equity ratio of 106.74. The company has a market capitalization of £75.18 billion, a P/E ratio of 13.24, a PEG ratio of 1.24 and a beta of 0.35.

GSK (LON:GSK - Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%.The company had revenue of GBX 762.90 billion for the quarter. As a group, sell-side analysts predict that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling at GSK

In related news, insider Luke Miels sold 15,579 shares of the stock in a transaction dated Friday, February 13th. The shares were sold at an average price of GBX 2,160, for a total value of £336,506.40. Also, insider Jonathan Symonds purchased 5,000 shares of the company's stock in a transaction that occurred on Friday, March 20th. The stock was acquired at an average cost of GBX 1,951 per share, with a total value of £97,550. Over the last ninety days, insiders bought 15,452 shares of company stock worth $32,135,952. 0.20% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.